Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-27 5:02 pm Sale | 2023-12-22 | 13D | POINT Biopharma Global Inc. PNT | SILBER ALLAN C | 0 0.000% | -9,316,184 (Position Closed) | Filing History |
| 2023-12-20 4:38 pm Sale | 2023-12-18 | 13D | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND LP | 0 0.000% | -17,437,375 (Position Closed) | Filing History |
| 2023-11-06 1:47 pm Purchase | 2023-11-02 | 13D | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND LP | 17,437,375 16.500% | 8,259,627 (+90.00%) | Filing History |
| 2023-10-03 2:57 pm Purchase | 2023-10-02 | 13D | POINT Biopharma Global Inc. PNT | SILBER ALLAN C | 9,316,184 8.800% | 84,816 (+0.92%) | Filing History |
| 2023-02-14 12:00 pm Purchase | 2022-12-31 | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND LP | 9,177,748 8.700% | 3,587,700 (+64.18%) | Filing History |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | POINT Biopharma Global Inc. PNT | BlackRock Inc. BLK | 5,393,438 5.100% | 5,393,438 (New Position) | Filing History |
| 2022-11-22 4:21 pm Purchase | 2022-11-17 | 13D | POINT Biopharma Global Inc. PNT | SILBER ALLAN C | 9,231,368 8.740% | 365,580 (+4.12%) | Filing History |
| 2022-09-26 5:29 pm Sale | 2022-09-26 | 13D | POINT Biopharma Global Inc. PNT | RA Capital Management, L.P. | 0 0.000% | -9,003,018 (Position Closed) | Filing History |
| 2022-09-26 4:54 pm Purchase | 2022-09-14 | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND LP | 5,590,048 5.400% | 2,669,522 (+91.41%) | Filing History |
| 2022-09-16 4:29 pm Unchanged | 2022-09-14 | 13D | POINT Biopharma Global Inc. PNT | RA Capital Management, L.P. | 9,003,018 8.650% | 0 (Unchanged) | Filing History |
| 2022-08-29 5:01 pm Purchase | 2022-08-25 | 13D | POINT Biopharma Global Inc. PNT | RA Capital Management, L.P. | 9,003,018 9.900% | 147,000 (+1.66%) | Filing History |
| 2022-02-14 5:46 pm Purchase | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | Perceptive Advisors LLC | 1,193,995 1.300% | 1,193,995 (New Position) | Filing History |
| 2022-02-14 4:17 pm Purchase | 2021-12-31 | 13G | Therapeutics Acquisition Corp. RACA | Boxer Capital LLC | 2,500,000 2.800% | 1,000,000 (+66.67%) | Filing History |
| 2022-02-14 3:36 pm Purchase | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | RIVERVIEW GROUP LLC | 24,187 0.000% | 24,187 (New Position) | Filing History |
| 2022-02-14 1:55 pm Unchanged | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | T. Rowe Price Associates, Inc. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-02-11 8:51 pm Purchase | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | BIOTECHNOLOGY VALUE FUND LP | 2,920,526 3.200% | 2,920,526 (New Position) | Filing History |
| 2022-02-11 5:17 pm Purchase | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | SUVRETTA CAPITAL MANAGEMENT, LLC | 2,672,863 3.000% | 2,672,863 (New Position) | Filing History |
| 2022-02-11 10:09 am Unchanged | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | Avoro Capital Advisors LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-02-07 1:46 pm Purchase | 2021-12-31 | 13G | POINT Biopharma Global Inc. PNT | FRANKLIN RESOURCES INC BEN | 773,700 0.900% | 773,700 (New Position) | Filing History |
| 2022-02-04 3:47 pm Sale | 2021-12-31 | 13G | Therapeutics Acquisition Corp. RACA | Wellington Management Group LLP | 0 0.000% | -877,832 (Position Closed) | Filing History |